Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry House

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 24, 2009
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferasesYong Liu, Jacqueline Ramírez, Larry House, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2010
The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidationYong Liu, Jacqueline Ramírez, Larry House, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|August 16, 2013
[Personalized targeted therapy for lung cancer]Kehua Wu, Larry House, Wanqing Liu, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|January 9, 2014
[Next-generation sequencing for lung cancer]Kehua Wu, R Stephanie Huang, Larry House, et al.
Future Oncology (London, England)|August 29, 2013
Next-generation sequencing for lung cancerKehua Wu, R Stephanie Huang, Larry House, et al.
International Journal of Molecular Sciences|October 31, 2012
Personalized targeted therapy for lung cancerKehua Wu, Larry House, Wanqing Liu, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|June 9, 2015
In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7Larry House, Jacqueline Ramirez, Michael Seminerio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2013
Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugsKehua Wu, Larry House, Jacqueline Ramírez, et al.
Pharmacogenetics and Genomics|August 24, 2010
A pharmacogenetic study of vorinostat glucuronidationSoonmo Peter Kang, Jacqueline Ramirez, Larry House, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2008
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumoursSamir D Undevia, Federico Innocenti, Jacqueline Ramirez, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 24, 2009
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferasesYong Liu, Jacqueline Ramírez, Larry House, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2010
The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidationYong Liu, Jacqueline Ramírez, Larry House, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|August 16, 2013
[Personalized targeted therapy for lung cancer]Kehua Wu, Larry House, Wanqing Liu, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|January 9, 2014
[Next-generation sequencing for lung cancer]Kehua Wu, R Stephanie Huang, Larry House, et al.
Future Oncology (London, England)|August 29, 2013
Next-generation sequencing for lung cancerKehua Wu, R Stephanie Huang, Larry House, et al.
International Journal of Molecular Sciences|October 31, 2012
Personalized targeted therapy for lung cancerKehua Wu, Larry House, Wanqing Liu, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|June 9, 2015
In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7Larry House, Jacqueline Ramirez, Michael Seminerio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2013
Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugsKehua Wu, Larry House, Jacqueline Ramírez, et al.
Pharmacogenetics and Genomics|August 24, 2010
A pharmacogenetic study of vorinostat glucuronidationSoonmo Peter Kang, Jacqueline Ramirez, Larry House, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2008
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumoursSamir D Undevia, Federico Innocenti, Jacqueline Ramirez, et al.
Pageof 2